Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis — Stella

Home/Hepatitis B/Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis

View on ClinicalTrials.gov

Recruiting

Back to Hepatitis B trials

Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis

Phase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.

Trial locations(1 site)

United States

Mercy Medical Center, Baltimore, Maryland

Key details

Phase

Post-approval study

Sponsor

Mercy Medical Center

Enrollment target

~200 participants

Started

September 2020

Primary completion

December 2028

Age range

18 Years and older

Last updated November 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.